Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - AVAX Technologies, Inc. (NasdaqNM:AVXT)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider
Recent Events
Aug  6Earnings Announcement
Location
4520 Main Street, Suite 930
Kansas City, MO 64111
Phone: (816) 960-1333
Fax: (816) 960-1334
Email: dtousley@avax-tech.com
Employees (last reported count): 54
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 27%
·Institutional: 5% (6% of float)
(19 institutions)
·Net Inst. Selling: 855.0K shares
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
AVAX Technologies, Inc. is a development stage biotechnology company with international operations, specializing in the development and commercialization of individualized therapies and other novel products and technologies for the treatment of cancer and other life-threatening diseases. AVAX's lead development program is a patented autologous cell technology, called AV Vaccine, that attempts to stimulate a patients own immune system to recognize, contain and eliminate cancer cells. In August 2000, AVAX acquired Genopoietic S.A. and its corporate affiliate, which develops cell and gene-based therapies in collaboration with Pierre et Marie Curie University and Centre National de la Recherche Scientifique. Through this acquisition, AVAX is developing a gene therapy technology based on the thymidine kinase gene to induce bone marrow and solid organ transplantation tolerance, for the treatment of cancer and other indications, and autologous chondrocytes for the repair of damaged cartilage.
More from Market Guide: Expanded Business Description

Financial Summary
AVAX Technologies, a development stage company, develops and commercializes novel biotechnologies, immunotherapies and pharmaceuticals for cancer and other life-threatening diseases. For the six months ended 6/30/01, revenues totalled $294 thousand, up from $0. Net loss increased 24% to $5.8 million. Results reflect the launch of M-Vax in Australia and the Genopoietic and GPH, S.A. acquisition, offset by the inclusion of acq. R&D and higher manufacturiang and R&D costs.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

David Tousley, 45
Interim Pres & CEO, Chief Financial Officer, Chief Operating Officer, Secy.
$252K
Warren Dudley, 46
Sr. VP of Sales, Marketing ad Bus. Devel.
279K
Richard Rainey, 34
VP of Fin. and Admin.
--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:AVXTAs of 31-Aug-2001
Price and Volume
52-Week Low
on 1-May-2001
$0.61 
Recent Price$1.60 
52-Week High
on 5-Sep-2000
$9.438
Beta1.31 
Daily Volume (3-month avg)55.8K
Daily Volume (10-day avg)16.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-82.5%
52-Week Change
relative to S&P500
-76.5%
Share-Related Items
Market Capitalization$26.5M
Shares Outstanding16.5M
Float12.1M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$1.34 
Earnings (ttm)-$1.02 
Earnings (mrq)-$0.15 
Sales (ttm)$0.02 
Cash (mrq)$1.01 
Valuation Ratios
Price/Book (mrq)1.19 
Price/EarningsN/A 
Price/Sales (ttm)66.09 
Income Statements
Sales (ttm)$406.0K
EBITDA (ttm)-$18.0M
Income available to common (ttm)-$17.4M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-56.85%
Return on Equity (ttm)-62.37%
Financial Strength
Current Ratio (mrq)12.47 
Debt/Equity (mrq)0.01 
Total Cash (mrq)$16.7M
Short Interest
As of 8-Aug-2001
Shares Short10.0K
Percent of Float0.1%
Shares Short
(Prior Month)
9,000 
Short Ratio0.11 
Daily Volume88.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.